Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417811 | 0.88 | MCHR1 (1.00) | MCHR1DRD2 | |
| SCHEMBL5419401 | 0.87 | MCHR1 (0.76) | MCHR1 | |
| SCHEMBL5423752 | 0.85 | MCHR1 (1.00) | MCHR1 | |
| SCHEMBL5420867 | 0.85 | MCHR1 (1.00) | MCHR1DRD2 | |
| SCHEMBL14489997 | 0.84 | MCHR1 (0.84) | MCHR1DRD2 | |
| Hydrochloric Acid SCHEMBL5416365 | 0.83 | MCHR1 (0.82) | MCHR1DRD2 | |
| Hydrochloric Acid SCHEMBL8790307 | 0.82 | HTR1A (0.60) | MCHR1DRD2 | |
| SCHEMBL5432164 | 0.82 | MCHR1 (0.70) | MCHR1 | |
| SCHEMBL3870116 | 0.81 | DRD2 (0.74) | MCHR1DRD2 | |
| SCHEMBL7850508 | 0.80 | ACHE (0.74) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-7229986-B2 | Melanin-concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LTD. (JP) | 2007-06-12 | — | — | US | disclosed |
| US-20030158177-A1 | Treating or preventing obesity | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1283199-A1 | MELANIN-CONCENTRATING HORMONE ANTAGONIST | Takeda Chemical Industries, Ltd. (JP) | 2003-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158177-A1 | Treating or preventing obesity | MCHR1, MC1R, NPY1R | MCHR1 1/4885DRD2 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.